These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 34328191)

  • 21. Impacts of gut microbiota alteration on age-related chronic liver diseases.
    Adhikary S; Esmeeta A; Dey A; Banerjee A; Saha B; Gopan P; Duttaroy AK; Pathak S
    Dig Liver Dis; 2024 Jan; 56(1):112-122. PubMed ID: 37407321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
    Leclercq S; de Timary P; Stärkel P
    Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan.
    Tsai MC; Liu YY; Lin CC; Wang CC; Wu YJ; Yong CC; Chen KD; Chuah SK; Yao CC; Huang PY; Chen CH; Hu TH; Chen CL
    Nutrients; 2020 Mar; 12(3):. PubMed ID: 32204538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
    Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
    Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of microbiota in nonalcoholic fatty liver disease.
    Di Ciaula A; Bonfrate L; Portincasa P
    Eur J Clin Invest; 2022 Jul; 52(7):e13768. PubMed ID: 35294774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Ter Arkh; 2017; 89(8):120-128. PubMed ID: 28914862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut microbiome and nonalcoholic fatty liver disease.
    Wu MY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):444-451. PubMed ID: 37308360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage.
    Plaza-Díaz J; Solís-Urra P; Rodríguez-Rodríguez F; Olivares-Arancibia J; Navarro-Oliveros M; Abadía-Molina F; Álvarez-Mercado AI
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of antibiotics and melatonin on hepato-intestinal inflammation and gut microbial dysbiosis induced by a short-term high-fat diet consumption in rats.
    Yildirim A; Arabacı Tamer S; Sahin D; Bagriacik F; Kahraman MM; Onur ND; Cayirli YB; Cilingir Kaya ÖT; Aksu B; Akdeniz E; Yuksel M; Çetinel Ş; Yeğen BÇ
    Br J Nutr; 2019 Oct; 122(8):841-855. PubMed ID: 31217044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.
    Kobayashi T; Iwaki M; Nakajima A; Nogami A; Yoneda M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer?
    Chattopadhyay I; Gundamaraju R; Jha NK; Gupta PK; Dey A; Mandal CC; Ford BM
    Dis Markers; 2022; 2022():2941248. PubMed ID: 35178126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far?
    Fukui H
    Diseases; 2019 Nov; 7(4):. PubMed ID: 31726747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
    Zeng Y; Chen S; Fu Y; Wu W; Chen T; Chen J; Yang B; Ou Q
    J Viral Hepat; 2020 Feb; 27(2):143-155. PubMed ID: 31600845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut Microbiota and Host Reaction in Liver Diseases.
    Fukui H
    Microorganisms; 2015 Oct; 3(4):759-91. PubMed ID: 27682116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal metabonomics combined with 16S rRNA gene sequencing to analyze the changes of gut microbiota in rats with kidney-yang deficiency syndrome and the intervention effect of You-gui pill.
    Chen R; Wang J; Zhan R; Zhang L; Wang X
    J Ethnopharmacol; 2019 Nov; 244():112139. PubMed ID: 31401318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut Microbiota and Liver Injury (II): Chronic Liver Injury.
    Baker SS; Baker RD
    Adv Exp Med Biol; 2020; 1238():39-54. PubMed ID: 32323179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.